CRISPR/Cas9: Molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer

Cancer Gene Therapy

Volumn 22, Issue 11, 2015, Pages 509-517

  Sachdeva, M ^a   Sachdeva, N ^b   Pal, M ^a   Gupta, N ^a   Khan, I A ^a   Majumdar, M ^a   Tiwari, A ^a  

^a Rajiv Gandhi Proudyogiki Vishwavidyalaya   (India)

^b D Y PATIL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; ATM PROTEIN; AZACITIDINE; B RAF KINASE; BETA CATENIN; CAVEOLIN 1; CISPLATIN; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; CRIZOTINIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 1; DOCETAXEL; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GUADECITABINE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ONARTUZUMAB; PROTEIN RET; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; SELINEXOR; UNCLASSIFIED DRUG; VALPROIC ACID;

CANCER GENE THERAPY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; EPISTASIS; HUMAN; LUNG CANCER; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; EPIGENETICS; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GENETICS; GENOME; GENOMICS; LUNG NEOPLASMS; METABOLISM; PROCEDURES; RNA EDITING;

ANIMALS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-ASSOCIATED PROTEINS; CRISPR-CAS SYSTEMS; EPIGENOMICS; GENE TARGETING; GENETIC ENGINEERING; GENETIC THERAPY; GENOME; GENOMICS; HUMANS; LUNG NEOPLASMS; RNA EDITING;

EID: 84947126779     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2015.54     Document Type: Review

References (80)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Tang M, Xu W, Wang Q, Xiao W, Xu R. Potential of DNMT and its epigenetic regulation for lung cancer therapy. Curr Genom 2009; 10: 336.
3. Xu XL, Wu LC, Du F, Davis A, Peyton M, Tomizawa Y et al. Inactivation of human SRBC, located within the 11p15. 5-p15. 4 tumor suppressor region, in breast and lung cancers. Cancer Res 2001; 61: 7943-7949.
4. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002; 3: 748-754.
5. Kremer M, Quintanilla-Martinez L, Fuchs M, Gamboa-Dominguez A, Haye S, Kalthoff H et al. Influence of tumor-Associated E-cadherin mutations on tumorigenicity and metastasis. Carcinogenesis 2003; 24:1879-1886.
6. Sloan EK, Stanley KL, Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 2004; 23: 7893-7897.
7. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
8. Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int Jo Cancer 2014; 135: 2223-2231.
9. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010; 19: 698-711.
10. Malecová B, Morris KV. Transcriptional gene silencing mediated by noncoding RNAs. Curr Opin Mol Ther 2010; 12: 214.
11. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
12. Han Z, Liu L, Liu Y, Li S. Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. Int J Clin Exp Pathol 2014; 7: 4774.
13. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007; 315: 1709-1712.
14. Garneau JE, Dupuis M-E, Villion M, Romero DA, Barrangou R, Boyaval P et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 2010; 468: 67-71.
15. Chylinski K, Le Rhun A, Charpentier E. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol 2013; 10: 726-737.
16. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 2014; 507: 62-67.
17. Cencic R, Miura H, Malina A, Robert F, Ethier S, Schmeing TM et al. Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage. PLoS One 2014; 9: e109213.
18. Anders C, Niewoehner O, Duerst A, Jinek M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 2014; 513: 569-573.
19. Haft DH, Selengut J, Mongodin EF, Nelson KE. A guild of 45 CRISPR-Associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. PLoS Comput Biol 2005; 1: e60.
20. Fenner MW. CRISPR-A widespread system that provides acquired resistance against phages in bacteria and archaea. Lawrence Berkeley Natl Lab 2007; 6: 181-186.
21. Barrangou R, Horvath P. CRISPR: new horizons in phage resistance and strain identification. Annu Rev Food Sci Technol 2012; 3: 143-162.
22. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 2012; 109: E2579-E2586.
23. Sorek R, Kunin V, Hugenholtz P. CRISPR-A widespread system that provides acquired resistance against phages in bacteria and archaea. Nat Rev Microbiol 2008; 6: 181-186.
24. Fonfara I, Le Rhun A, Chylinski K, Makarova KS, Lécrivain A-L, Bzdrenga J et al. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Res 2014; 42: 2577-2590.
25. Hou Z, Zhang Y, Propson NE, Howden SE, Chu L-F, Sontheimer EJ et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci USA 2013; 110: 15644-15649.
26. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-821.
27. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 2013; 31: 233-239.
28. Cradick TJ, Fine EJ, Antico CJ, Bao G. CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-Darget activity. Nucleic Acids Res 2013; 41: 9584-9592.
29. Sinkunas T, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V. Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. EMBO J 2011; 30: 1335-1342.
30. Fineran PC, Charpentier E. Memory of viral infections by CRISPR-Cas adaptive immune systems: acquisition of new information. Virology 2012; 434: 202-209.
31. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013; 152: 1173-1183.
32. Westra ER, Semenova E, Datsenko KA, Jackson RN, Wiedenheft B, Severinov K et al. Type IE CRISPR-cas systems discriminate target from non-Darget DNA through base pairing-independent PAM recognition. PLoS Genet 2013; 9: e1003742.
33. Cho SW, Kim S, Kim JM, Kim J-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013; 31: 230-232.
34. Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA, Musunuru K. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 2013; 12: 393.
35. Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 2013; 13: 659-662.
36. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013; 153: 910-918.
37. Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res 2014; 42: e147.
38. Yoshimi K, Kaneko T, Voigt B, Mashimo T. Allele-specific genome editing and correction of disease-Associated phenotypes in rats using the CRISPR-Cas platform. Nat Commun 2014; 5: 4240.
39. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013; 154: 442-451.
40. Nekrasov V, Staskawicz B, Weigel D, Jones JD, Kamoun S. Targeted mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided endonuclease. Nat Biotechnol 2013; 31: 691-693.
41. Shan Q, Wang Y, Li J, Zhang Y, Chen K, Liang Z et al. Targeted genome modification of crop plants using a CRISPR-Cas system. Nat Biotechnol 2013; 31: 686-688.
42. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 2014; 32: 347-355.
43. Ran F, Hsu PD, Lin C-Y, Gootenberg JS, Konermann S, Trevino AE et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013; 154: 1380-1389.
44. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 2013; 10: 973-976.
45. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res 2013; 41: 7429-7437.
46. Lawhorn IE, Ferreira JP, Wang CL. Evaluation of sgRNA target sites for CRISPR-mediated repression of TP53. PLoS One 2014; 9: e113232.
47. Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 2015; 33: 510-517.
48. Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW et al. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 2013; 23: 1163-1171.
49. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428: 431-437.
50. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 2008; 105: 20380-20385.
51. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L et al. Widespread siRNA" off-Darget" transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12: 1179-1187.
52. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 2013; 31: 833-838.
53. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014; 343: 84-87.
54. Gersbach CA, Perez-Pinera P. Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine. Expert Opin Ther Targets 2014; 18: 835-839.
55. Zhao Y, Dai Z, Liang Y, Yin M, Ma K, He M et al. Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system. Sci Rep 2014; 4: 3943.
56. Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS et al. CRISPRmediated direct mutation of cancer genes in the mouse liver. Nature 2014; 514: 380-384.
57. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014; 159: 440-455.
58. Zhou Q, Derti A, Ruddy D, Rakiec D, Kao I, Lira M et al. A chemical genetics approach for the functional assessment of novel cancer genes. Cancer Res 2015; 75: 1949-1958.
59. Li J, Shou J, Guo Y, Tang Y, Wu Y, Jia Z et al. Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR/Cas9. J Mol Cell Biol 2015; 7: 284-298.
60. Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han Y-C et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 2014; 516: 423-427.
61. Liu Y, Zeng Y, Liu L, Zhuang C, Fu X, Huang W et al. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat Commun 2014; 5: 5393.
62. Kasap C, Elemento O, Kapoor TM. DrugTargetSeqR: a genomics-And CRISPR-Cas9-based method to analyze drug targets. Nat Chem Biol 2014; 10: 626-628.
63. Neggers JE, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S et al. Identifying drug-Darget selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol 2015; 22: 107-116.
64. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 2015; 33: 661-667.
65. Zhen S, Hua L, Takahashi Y, Narita S, Liu Y-H, Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Commun 2014; 450: 1422-1426.
66. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
67. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
68. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68: 3389-3395.
69. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
70. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
71. Roberts P, Der C. Targeting the Raf-MEK-ERK mitogen-Activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310.
72. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
73. Ju YS, Lee W-C, Shin J-Y, Lee S, Bleazard T, Won J-K et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012; 22: 436-445.
74. Birchmeier C, Birchmeier W, Gherardi E, Woude GFV. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
75. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-1488.
76. Belinsky SA, Klinge DM, Stidley CA, Issa J-P, Herman JG, March TH et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63: 7089-7093.
77. Chu B, Karpenko M, Liu Z, Aimiuwu J, Villalona-Calero M, Chan K et al. Phase I study of 5-Aza-2'-deoxycytidine in combination with valproic acid in non-smallcell lung cancer. Cancer Chemother Pharmacol 2013; 71: 115-121.
78. Lin R-K, Wang Y-C. A DNA methyltransferase I inhibitor mithramycin A in cancer cells: a pilot study. Bioformosa 2007; 42: 55-62.
79. Pan M-R, Chang H-C, Chuang L-Y, Hung W-C. The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Exp Biol Med 2008; 233: 456-462.
80. Yu X-D, Wang S-Y, Chen GA, Hou C-M, Zhao M, Hong JA et al. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J 2007; 13: 105-113.